wla(warner lambert) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Anthony Wong who wrote (809)	6/10/1999 10:10:00 PM
From: Captain Jack	Read Replies (1) of 942

Tony-- from BM mgmt,, Bristol Myers (BMY: news, msgs) is seeing a dramatically improved picture for its pipeline, said Vice Chairman Kenneth Wag. Revenue growth will be driven by increased volume. The company's near-term strategy includes targeting high growth drugs including those that treat HIV and cholesterol. The company plans to be "a major player" in 12-14 markets around the world. Cholesterol drug Pravachol is "under pressure" from Warner-Lambert's (WLA: news, msgs) Lipitor. Wag also said he has high hopes for Omapatrilat, a hypertension drug. The company expects to file for marketing approval in November or December of this year. He billed it "the biggest single opportunity that exists" at Bristol-Myers with "blockbuster potential." He pledged to accelerate earnings growth so that investors will regard the drug maker as a growth company rather than the value company of the past. WLA sure does NOT look like a "growth company"...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next